Substance abuse in schizophrenia: A review

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 3, 1998, Pages 26-30

  Buckley, Peter F ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CAFFEINE; CLOZAPINE; COCAINE; HALOPERIDOL; NEUROLEPTIC AGENT; NICOTINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AKINESIA; ALCOHOL ABUSE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DYSPHORIA; HUMAN; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SMOKING; SUBSTANCE ABUSE;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; COMORBIDITY; COST-BENEFIT ANALYSIS; DIAGNOSIS, DUAL (PSYCHIATRY); DRUG MONITORING; HUMANS; PRECIPITATING FACTORS; PREVALENCE; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 0031977231     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the epidemiologic catchment area (ECA) study. JAMA 1990;264:2511-2518
2. Young CR, Longhurst JG, Bowers MB Jr, et al. The expanding indications for clozapine. Exp Clin Psychopharmacol 1997;5(3):216-234
3. Tsuang MT, Simpson JC, Kronfol Z. Subtypes of drug abuse with psychosis: demographic characteristics, clinical features, and family history. Arch Gen Psychiatry 1982;39:141-147
4. Noble EP, St Jeor ST, Ritchie T, et al. D2 dopamine receptor gene and cigarette smoking: a reward gene? Med Hypotheses 1994;42:257-260
5. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997;23:247-254
6. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985;142:1259-1264
7. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993;19:609-618
8. Voruganti LN, Heslegrave RJ, Awad AG. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J Nerv Ment Dis 1997;185(7):463-465
9. Brady K, Anton R, Ballenger JC, et al. Cocaine abuse among schizophrenic patients. Am J Psychiatry 1990;147:1164-1167
10. Lopez W, Jeste DV. Movement disorders and substance abuse. Psychiatr Serv 1997;48:634-636
11. Drake RE, Bartels SJ, Teague GB, et al. Treatment of substance abuse in severely mentally ill patients. J Nerv Ment Dis 1993;181(10):606-611
12. Dixon L, Haas G, Weiden PJ, et al. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 1991;148:224-230
13. Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia: a prospective community study. J Nerv Ment Dis 1989;177(7):408-414
14. Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry 1996;40:1155-1163
15. Hymowitz N, Jaffe FE, Gupta A, et al. Cigarette smoking among patients with mental retardation and mental illness. Psychiatr Serv 1997;48(1): 100-102
16. Kosten TR, Ziedonis DM. Substance abuse and schizophrenia: editors' introduction. Schizophr Bull 1997;23:181-186
17. De Leon J, Dadvand M, Canuso C, et al. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 1995;152: 453-455
18. Ziedonis DM, Kosten TR, Glazer WM, et al. Nicotine dependence and schizophrenia. Hospital and Community Psychiatry 1994;45(3):204-206
19. Adler LE, Hoffer LD, Wiser A, et al. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993;150: 1856-1861
20. Schneier FR, Siris SG. A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice. J Nerv Ment Dis 1987;175(11): 641-652
21. Ziedonis D, Richardson T, Lee E, et al. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol Bull 1992;28: 309-314
22. Ball SA, Carroll KM, Babor TF, et al. Subtypes of cocaine abusers: support for a type A-type B distinction. J Consult Clin Psychol 1995;63(1): 115-124
23. Kovasznay B, Fleischer J, Tanenberg-Karant M. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 1997;23:195-201
24. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994;51: 273-279
25. Allebeck P, Adamsson C, Engström A. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatr Scand 1993;88:21-24
26. D'Mello DA, Boltz MK, Msibi B. Relationship between concurrent substance abuse in psychiatric patients and neuroleptic dosage. Am J Drug Alcohol Abuse 1995;21(2):257-265
27. Bowers MB Jr, Mazure CM, Nelson JC, et al. Psychotogenic drug use and neuroleptic response. Schizophr Bull 1990;16:81-85
28. Owen RR, Fischer EP, Booth BM. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996;47 (8):853-858
29. Pristach CA, Smith CM. Medication compliance and substance abuse among schizophrenic patients. Hospital and Community Psychiatry 1990;41(12):1345-1348
30. Gupta S, Hendricks S, Kenkel AM, et al. Relapse in schizophrenia: is there a relationship to substance abuse? Schizophr Res 1996;20:153-156
31. Swofford CD, Kasckow JW, Scheller-Gilkey G, et al. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res 1996;20: 145-151
32. Richard ML, Liskow BI, Perry PJ. Recent psychostimulant use in hospitalized schizophrenics. J Clin Psychiatry 1985;46:79-83
33. Dixon L, Weiden PJ, Haas G, et al. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry 1992;33(2):121-122
34. Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia in psychiatric patients with substance use disorders. Am J Drug Alcohol Abuse 1990;16 (1-2):57-66
35. Bailey L, Maxwell S, Brandabur MM. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients. Psychopharmacol Bull 1997;33(1):177-181
36. Zaretsky A, Rector NA, Seeman MV, et al. Current cannabis use and tardive dyskinesia. Schizophr Res 1993;11:3-8
37. Buckley PF. Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia. J Subst Abuse Treat. In press
38. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine [letter]. Am J Psychiatry 1995;152:959
39. McEvoy J, Freudenreich O, McGee M, et al. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 1995;37:550-552
40. Albanese MJ, Khantzian EJ, Murphy SL. Decreased substance use in chronically psychotic patients treated with clozapine [letter]. Am J Psychiatry 1994;151:780-781
41. Frankenburg FR. Experience with clozapine in refractory psychotic illnesses. In: Standards of Care in Schizophrenia - Proceedings of a Consensus Conference. Sandoz Pharmaceutical Corporation; 1994:3-19
42. Kosten TR, Nestler EJ. Clozapine attenuates cocaine conditioned place preference. Life Sci 1994;55(1):PL9-14
43. Roberts DC, Vickers G. Atypical neuroleptics increase self-administration of cocaine: an evaluation of a behavioural screen for antipsychotic activity. Psychopharmacology (Berl) 1984;82:135-139
44. Vanover KE, Piercey MF, Woolverton WL. Evaluation of the reinforcing and discriminative stimulus effects of cocaine in combination with (+)-AJ 76 or clozapine. J Pharmacol Exp Ther 1993;266:780-789
45. Yovell Y, Opler LA. Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abuser: a case report and a hypothesis. J Nerv Ment Dis 1994;182(10):591-592
46. Buckley P, Thompson PA, Way L, et al. Substance abuse and clozapine treatment. J Clin Psychiatry 1994;55(9, suppl B):114-116
47. Conley R, Gale E, Hirsch K. Olanzapine response in therapy-refractory schizophrenia with substance abuse (SA) [abstract]. Schizophr Res 1997; 24:190
48. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992;13:177-184
49. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988;85:5274-5278
50. Criswell HE, Mueller RA, Breese GA. Clozapine antagonism of D-1 and D-2 dopamine receptor-mediated behaviors. Eur J Pharmacol 1989;159: 141-147
51. Feldman J. Clozapine and agranulocytosis. Psychiatr Serv 1996;47(11): 1177-1178
52. Research on mental illness and addictive disorders: progress and prospects: a report of the Board on Mental Health and Behavioral Medicine, Institute of Medicine. Am J Psychiatry 1985;142(7 suppl):1-41
53. Buckley PF. Treatment of schizophrenia: let's talk dollars and sense. Am J Managed Care. In press
54. Bartels SJ, Teague GB, Drake RE, et al. Substance abuse in schizophrenia: service utilization and costs. J Nerv Ment Dis 1993;181(4):227-232
55. De Quardo JR, Carpenter CF, Tandon R. Patterns of substance abuse in schizophrenia: nature and significance. J Psychiatr Res 1994;28(3): 267-275
56. Shaner A, Eckman TA, Roberts LJ, et al. Disability income, cocaine use, and repeated hospitalization among schizophrenic cocaine abusers: a government-sponsored revolving door? N Engl J Med 1995;333:777-783
57. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996;57(suppl 9):66-76
58. Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hospital and Community Psychiatry 1990;41(8): 882-885
59. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-1638
60. Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993;162:38-42